PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Dibondrin - Ampoules. Active substance: diphenhydramine hydrochloride

Similar documents
PACKAGE LEAFLET: INFORMATION FOR THE USER. Dibondrin liquid. Active substance: diphenhydramine hydrochloride

Package Information Leaflet: Information for the user. Calmaben Coated Tablets

Package leaflet: Information for the patient. Chlorphenamine 10 mg/ml Solution for Injection (Chlorphenamine Maleate)

PACKAGE LEAFLET: INFORMATION FOR THE USER. EPHEDRINE HCl STEROP 10mg/ml EPHEDRINE HCl STEROP 50mg/ml Solution for injection. Ephedrine Hydrochloride

AVIOMARIN 50 mg tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER. Cathejell with Lidocaine anaesthetising gel (sterile single-use form)

Package leaflet: Information for the patient. Vertigon 8 mg Tablets Vertigon 16 mg Tablets (betahistine dihydrochloride)

Package leaflet: Information for the patient. xylometazoline hydrochloride

Package Leaflet: INFORMATION FOR THE USER. PARACODIN 10 mg/g oral drops, solution (dihydrocodeine hydrorhodanide)

Package leaflet: Information for the user

Package leaflet: Information for the user. Morfin Abcur 10 mg/ml, solution for injection. morphine hydrochloride

Package leaflet: Information for the user Glycopyrronium Bromide 200 micrograms/ml injection (Glycopyrronium Bromide)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Otrivin Menthol (without preservative) 1 mg/ml nasal spray, solution Xylometazoline hydrochloride

Package leaflet: Information for the patient. Morphine Unimedic 1 mg/ml solution for injection morphine hydrochloride trihydrate

Package leaflet: Information for the patient. / / 30 mg/5 ml syrup. Ambroxol hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Nasonal 1 mg/ml neusspray, oplossing. Xylometazoline hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER Paracodin 0.20% w/w Syrup (dihydrocodeine hydrogen tartrate)

Package leaflet: Information for the user

Package leaflet: Information for the user. Cetiristad 10 mg film-coated tablets Cetirizine dihydrochloride

Package leaflet: Information for the patient. Acetylsalicylic acid Bluefish 75 mg tablets Acetylsalicylic acid Bluefish 160 mg tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol

Package leaflet: Information for the patient

Package leaflet: Information for the patient

Package leaflet: Information for the patient. Bromhexin Krewel Meuselbach Drops 12 mg/ml. Bromhexine hydrochloride

XYZAL 5 MG FILM-COATED TABLET

PACKAGE LEAFLET. Page 1 of 6

1. What Miacalcic is and what it is used for

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. ILAXTEN 20 MG TABLETS bilastine

Package leaflet: Information for the user. Cyclizine Lactate 50 mg/ml Injection

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xylonase 0.1% w/v Nasal Spray, Solution Xylometazoline hydrochloride

PATIENT INFORMATION LEAFLET. Nasoxyl nasal spray solution 1 mg/ml

Package leaflet: Information for the user NON DROWSY SUDAFED. DECONGESTANT 60 mg FILM-COATED TABLETS Pseudoephedrine hydrochloride

Package leaflet: Information for the patient. Brimonidine Biogaran 2 mg/ml eye drops, solution. brimonidine tartrate

PACKAGE LEAFLET: INFORMATION FOR THE USER. ZADITEN 1 mg/5 ml Oral Solution. Ketotifen (as Ketotifen hydrogen fumarate)

TOULARYNX DEXTROMETHORPHAN FORTE 3 mg/ml, syrup Dextromethorphan HBr monohydrate

TRIPROLIDINE. Please read this leaflet and the packaging of the medicine you purchased, carefully before you start using triprolidine.

HERNOVIR 200 mg tablets

1. What Betahistine dihydrochloride tablets is and what it is used for

Package leaflet: Information for the patient. Tranexamic Acid 100 mg/ml, Solution for Injection tranexamic acid

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride

Package leaflet: Information for the user. Ebateva 20 mg Orodispersible Tablets. Ebastine

PACKAGE LEAFLET Package leaflet: Information for the user. Ranitidin Actavis 150 mg and 300 mg film-coated tablets. Ranitidine

Package leaflet: Information for the patient. Torarese 2.5 mg tablets Torarese 5 mg tablets Torarese 10 mg tablets Torarese 20 mg tablets.

Package leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Xylo-COMOD

Package leaflet: Information for the user. Lidocaine Hydrochloride 1% w/v Solution for Injection Lidocaine Hydrochloride

Package leaflet: Information for the User Clarityn 10 mg tablets Loratadine

Benylin Children's Coughs & Colds 5mg/0.625mg per 5ml Syrup dextromethorphan, triprolidine

Package leaflet: Information for users. Imodium 2 mg orodispersible tablets Loperamide hydrochloride

Package leaflet: Information for the user. Melatonin Pharma Nord 3 mg, film-coated tablets melatonin

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

PACKAGE LEAFLET: INFORMATION FOR THE USER. Dopamine 40 mg/ml Sterile Concentrate

Package leaflet: Information for the user. Omnilax 10 g powder for oral solution, sachet. Macrogol 4000

Package leaflet: Information for the user. Atropin Stragen 0.1 mg/ml solution for injection in prefilled syringe.

PACKAGE LEAFLET: INFORMATION FOR THE USER. SALAGEN 5 mg film-coated tablets. Pilocarpine hydrochloride

Package leaflet: Information for the patient. Dexametason Abcur 4 mg tablets. Dexamethasone

Package leaflet: Information for the User Clarityn 1 mg/ml syrup Loratadine

PACKAGE LEAFLET: INFORMATION FOR THE USER. Active substance: enoximone

Package leaflet: Information for the user Cyklokapron 500 mg Solution for Injection tranexamic acid

Package leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine)

Package leaflet: Information for the user. Co-Codamol 30mg/500mg Capsules (Codeine Phosphate Hemihydrate and Paracetamol)

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

TREANA 5mg and 10mg Film-coated Tablets

Package leaflet: Information for the patient Tranexamic acid 100 mg/ml Solution for Injection tranexamic acid

FLUIMUKAN PLUS 600 mg effervescent tablets

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER. DF118 Tablets 30mg (Dihydrocodeine Hydrogen Tartrate)

PATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:

Package leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE USER. EASOFEN MAX STRENGTH 400mg FILM-COATED TABLETS. Ibuprofen

PACKAGE LEAFLET: INFORMATION FOR THE USER. BritLofex Tablets 0.2mg LOFEXIDINE HYDROCHLORIDE

Package leaflet: Information for the user. <PRODUCT NAME> 10 g powder for oral solution in sachet Macrogol 4000

SINGULAIR JUNIOR 5mg chewable tablets

Package Leaflet: Information for the user Kemadrin 5 mg Tablets Procyclidine hydrochloride

Irbenida H 150mg/12,5mg film-coated tablets

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

Pravat 40 mg tablets. Pravastatin sodium

Package Leaflet: Information for the user. Methocarbamol 750mg Film-Coated Tablets

PATIENT INFORMATION LEAFLET

PACKAGE LEAFLET: INFORMATION FOR THE USER Alfuzosin Sandoz 5 mg, prolonged-release tablets. Alfuzosin hydrochloride

Package leaflet: Information for the patient

PACKAGE LEAFLET: INFORMATION FOR THE USER ZIRPINE 10mg TABLETS Cetirizine dihydrochloride

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

Package leaflet: Information for the user. {Product name} 100 mg/100 mg/1 mg/20 mg/2 ml solution for injection

PACKAGE LEAFLET: INFORMATION FOR THE USER

PATIENT INFORMATION LEAFLET. MIDORYX (MIDAZOLAM INJECTION 5mg, 10mg BP)

Azelastine Nasal Spray 1 mg / 1 ml

Package leaflet: Information for the user

SPASMEX FORTE 5mg tablets

Package Leaflet: Information for the User Zotron 4mg/2ml (ή 8mg/4ml) Solution for Injection or Infusion ondansetron

Package leaflet: Information for the user

Ventolin Injection 500 micrograms/ml salbutamol sulfate

PACKAGE LEAFLET: INFORMATION FOR THE USER. Meptid 100 mg/ml Solution for Injection. Meptazinol Hydrochloride

Package leaflet: Information for the user. Nocdurna 25 microgram oral lyophilisate Nocdurna 50 microgram oral lyophilisate.

Package leaflet: Information for the user Efedrin Stragen 3mg/ml, solution for injection Ephedrine hydrochloride

Package leaflet: Information for the user. Tianeptine 12.5 mg Film Coated Tablets (Tianeptine Sodium)

Transcription:

Page 1 of 6 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Dibondrin - Ampoules Active substance: diphenhydramine hydrochloride Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Dibondrin - Ampoules are and what they are used for 2. What you need to know before you use Dibondrin - Ampoules 3. How to use Dibondrin - Ampoules 4. Possible side effects 5. How to store Dibondrin - Ampoules 6. Contents of the pack and other information 1. What Dibondrin Ampoules are and what they are used for Dibondrin Ampoules are indicated in adults, adolescents and children aged 2 years and older. This medicine is intended for intravenous and intramuscular injection in adults and children. Use as an antihistamine and antiallergic agent Diphenhydramine hydrochloride, the active substance of Dibondrin Ampoules, is a tried-and-tested agent for the prevention and acute treatment of shock caused by allergies. In combination with epinephrine (adrenaline), Dibondrin is an effective agent to treat anaphylactic shock. Prevention and acute treatment of immediate-type allergies influenced by histamine, such as hives, itching, skin inflammation, angioedema (extensive skin swelling), allergic rhinitis, allergies to pollen, food and medicines, hypersensitivity reactions of the skin caused by allergic reactions and swollen mucous membranes. Use as a sleeping aid and sedative Dibondrin is a sleeping aid used in patients who have problems falling and staying asleep (restlessness, nervousness, exhaustion). It makes falling asleep easier and prolongs the duration of sleep in sleep disorders, which are accompanied by itching or allergic symptoms. 2. What you need to know before you use Dibondrin Ampoules Do not use Dibondrin Ampoules - if you are allergic to diphenhydramine hydrochloride or any of the other ingredients of this medicine (listed in section 6). - during the first 3 months of pregnancy - during breast-feeding

Page 2 of 6 - in newborn infants and children under 2 years of age - if you are having an acute asthma attack. - if you have an adrenal tumour (phaeochromocytoma). - if you have narrow-angle glaucoma. - if you have a seizure disorder (e.g. epilepsy). - if you are currently using certain medicines (e.g. for heart rhythm disorders) that prolong the QT interval (certain ECG abnormalities that your doctor will identify). Warnings and precautions Please talk to your doctor or pharmacist before taking Dibondrin - Ampoules. Take special care using Dibondrin - Ampoules - if you suffer from chronic breathing problems and asthma, - if you have a stomach or intestinal ulcer or suffer from a narrowing of the stomach outlet, - if you have an enlarged prostate and your urine outflow is impaired, - if you have a heart function problem or a heart rhythm disorder, - if you have an overactive thyroid. - If liver and renal function is impaired, the dose should be restricted (see section Dosage ). Dibondrin Ampoules contain sodium, but less than 1 mmol (23 mg) sodium per ampoule, i.e. essentially sodium-free. 24 hours before performing allergy tests, Dibondrin must be discontinued. Other medicines and Dibondrin Ampoules Tell your doctor or pharmacist if you are taking / using, have recently taken / used or might take / use any other medicines. Dibondrin Ampoules should not be used at the same time as medicines containing diphenhydramine or other H 1 -antihistamines (certain antiallergic agents), as this may mutually enhance the effect of both medicines in an unpredictable manner. Due to possible enhanced effects on the heart (prolongation of the QT interval, i.e. ECG abnormalities that your doctor will identify), combined use of Dibondrin and medicines to treat heart rhythm disorders must be avoided. The effects may be enhanced during combined use of medicines that suppress the central nervous system (psychotropic agents, antidepressants, sleeping aids, painkillers, anaesthetics) and alcohol. Dibondrin must not be used at the same time as monoamine oxidase inhibitors (certain medicines for Parkinson s disease and depression), as these may enhance the effect. This also applies to the coadministration of other substances with anticholinergic effects, such as atropine, biperiden and tricyclic antidepressants. Dibondrin enhances the effect of adrenaline, noradrenaline and other sympathomimetic agents. The use of medicines for high blood pressure that act on the CNS (such as guanabenz, clonidine, methyldopa) together with Dibondrin may lead to increased tiredness. Dibondrin Ampoules with food, drink and alcohol Concomitant intake of alcohol may enhance the effect in an unpredictable manner. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Page 3 of 6 Dibondrin Ampoules must not be used in the first 3 months of pregnancy, as there is an increased risk of cleft palate formation. During the remainder of pregnancy, Dibondrin Ampoules should be used only after a careful benefit/risk assessment by the doctor and after the individual dose has been established. Repeated use during pregnancy is not recommended. Dibondrin Ampoules must not be used during breast-feeding. Driving and using machines! Do not drive or use machines because Dibondrin causes drowsiness and impairs reaction skills. This applies particularly in combination with alcohol. When administered after midnight, impaired reaction skills (a hangover) can be expected the following morning. Dibondrin Ampoules contain sodium Dibondrin Ampoules contain sodium, but less than 1 mmol (23 mg) sodium per ampoule, i.e. essentially sodium-free. 3. How to use Dibondrin Ampoules This medicine is administered only by a doctor or medically trained nursing staff. Slow intravenous or deep intramuscular injection (IV: maximum 25 mg/min), do not mix with other solutions for injection in the same syringe. The recommended dose is for adults and adolescents aged 12 years and older: Antihistamine, antiallergic agent: 1 2 ampoules, 3 times daily Sleeping aid and sedative: 1 2 ampoules as a single dose before bedtime for children aged 2 years and older: Antihistamine, antiallergic agent: Sleeping aid and sedative: 1 ampoule per 18 kg body weight, 3 times daily ½ ampoule per 18 kg body weight as a single dose before bedtime The maximum daily dose is for: Adults: 400 mg Children: 300 mg In elderly or debilitated patients and patients with severe liver or kidney damage, the dosage should be carefully adjusted to the clinical picture (see below). Dosage for elderly patients: Possibly use a lower starting dose, as side effects (dizziness, sedation, drop in blood pressure) are more likely to occur. Dosage for patients with impaired kidney function: An increase in the dosing interval to 6-12 hours (GFR 10-50mL/min) or 12-18 hours (GFR <10mL/min) is recommended. There have been no clinical studies with repeated doses. Dosage for patients with liver cirrhosis:

Page 4 of 6 Delayed excretion. Safe and effective as an intravenous single dose. There have been no clinical studies with repeated doses. Dibondrin Ampoules are primarily used for acute treatment; there are no results available for longterm, interval-free treatment with parenteral diphenhydramine. If you use more Dibondrin Ampoules than you should As this medicine is administered by the doctor or by medically trained nursing staff, an overdose is unlikely. To date, no case of overdose with Dibondrin - Ampoules has been reported. However, if an overdose with Dibondrin should nevertheless occur, it will be characterised by centrally controlled symptoms such as restlessness, heightened muscle reflexes, unconsciousness, shortness of breath or even cardiovascular arrest. Other signs are pupil dilation, racing heart, fever, hot and red skin, dry mucous membranes and symptoms similar to atropine poisoning. In this case, please contact a doctor immediately. If you forget to use Dibondrin Ampoules Do not use a double dose to make up for a forgotten dose. If you stop using Dibondrin Ampoules If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 4. Possible side effects Like all medicines, this medicine can cause side effects, although not everybody gets them. Side effects may occur at the following frequencies: Very common ( 1/10) Common ( 1/100, <1/10) Uncommon ( 1/1,000, <1/100) Rare ( 1/10,000, <1/1,000) Very rare (<1/10,000) Not known (cannot be estimated from the available data) Cardiac and vascular disorders Uncommon: circulatory problems Rare: racing heart Blood and lymphatic system disorders Very rare: blood count changes (a lack of certain blood cells) Nervous system disorders Very commonly ( 1/10) tiredness occurs. This is intended when used as a sleeping aid; when used as an antihistamine and antiallergic agent, this is a side effect. Uncommon: dizziness, drowsiness, headache, impaired concentration and coordination, muscle weakness. When administered during the night, a morning hangover (impaired reaction skills) can be expected, depending on the timing and dosage. Very rare, especially in children: central excitation, such as restlessness, irritability, anxiety and tremor.

Page 5 of 6 Eye disorders Uncommon: visual disturbances, increased inner eye pressure Respiratory and thoracic disorders Uncommon: thickening of bronchial mucus, breast tenderness Gastrointestinal disorders, renal and urinary disorders Uncommon: gastrointestinal complaints and bladder voiding problems Skin and subcutaneous tissue disorders Uncommon: dry mouth, nose and throat. Rare: allergic skin reactions, skin irritation and photosensitivity of the skin (avoid direct sun exposure). General disorders and administration site conditions Uncommon: increased blood flow and increased sensitivity at the injection site. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Bundesamt für Sicherheit im Gesundheitswesen Traisengasse 5 1200 WIEN ÖSTERREICH Fax: + 43 (0) 50 555 36207 Website: http://www.basg.gv.at/ By reporting side effects you can help provide more information on the safety of this medicine. 5. How to store Dibondrin Ampoules Do not freeze. Store in the original package in order to protect from light. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date, which is stated on the container after EXP. The expiry date refers to the last day of that month. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. Contents of the pack and other information What Dibondrin Ampoules contain - The active substance is: diphenhydramine hydrochloride - The other ingredients are: sodium chloride, water for injections, hydrochloric acid solution for ph adjustment What Dibondrin Ampoules look like and contents of the pack Colourless, clear solution for injection. Pack with 5 glass ampoules (glass type I), each containing 2 ml.

Page 6 of 6 Marketing Authorisation Holder and Manufacturer Pharm. Fabrik Montavit Ges.m.b.H. 6067 Absam Austria tel.: +43 5223 57926 0 fax: +43 5223 52294 e-mail: pharma@montavit.com MA No.: 7162 This leaflet was last revised in June 2014. --------------------------------------------------------------------------------------------------------------------- Note for the physician: Measures in the event of overdose: Clinical surveillance. Treatment of an overdose is symptomatic. Vasopressors can be given for hypotension and diazepam or thiopental for seizures. As an antidote, physostigmine salicylate after a physostigmine test is recommended. Do not administer any stimulants.